CN114746097A - 瑞波西汀治疗神经***障碍的用途 - Google Patents

瑞波西汀治疗神经***障碍的用途 Download PDF

Info

Publication number
CN114746097A
CN114746097A CN202080083484.4A CN202080083484A CN114746097A CN 114746097 A CN114746097 A CN 114746097A CN 202080083484 A CN202080083484 A CN 202080083484A CN 114746097 A CN114746097 A CN 114746097A
Authority
CN
China
Prior art keywords
reboxetine
narcolepsy
cataplexy
week
antidepressants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080083484.4A
Other languages
English (en)
Chinese (zh)
Inventor
赫里奥特·塔布提奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/740,329 external-priority patent/US20200147093A1/en
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Priority claimed from PCT/US2020/062560 external-priority patent/WO2021113163A1/en
Publication of CN114746097A publication Critical patent/CN114746097A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080083484.4A 2019-12-03 2020-11-30 瑞波西汀治疗神经***障碍的用途 Pending CN114746097A (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962943077P 2019-12-03 2019-12-03
US62/943,077 2019-12-03
US201962946295P 2019-12-10 2019-12-10
US62/946,295 2019-12-10
US16/740,329 2020-01-10
US16/740,329 US20200147093A1 (en) 2018-10-15 2020-01-10 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 2020-01-11
US16/740,411 US20200147096A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,411 2020-01-11
US16/740,410 2020-01-11
US16/740,410 US20200147095A1 (en) 2018-10-15 2020-01-11 Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US16/740,409 US11351175B2 (en) 2018-10-15 2020-01-11 Use of reboxetine to treat narcolepsy
PCT/US2020/062560 WO2021113163A1 (en) 2019-12-03 2020-11-30 Use of reboxetine to treat nervous system disorders

Publications (1)

Publication Number Publication Date
CN114746097A true CN114746097A (zh) 2022-07-12

Family

ID=81851750

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080083484.4A Pending CN114746097A (zh) 2019-12-03 2020-11-30 瑞波西汀治疗神经***障碍的用途

Country Status (12)

Country Link
EP (1) EP4069244A4 (de)
JP (1) JP2023504685A (de)
KR (1) KR20220108122A (de)
CN (1) CN114746097A (de)
AU (1) AU2020395082A1 (de)
BR (1) BR112022010677A2 (de)
CA (1) CA3163505A1 (de)
CO (1) CO2022007507A2 (de)
CR (1) CR20220247A (de)
IL (1) IL293536A (de)
MX (1) MX2022006630A (de)
PE (1) PE20230181A1 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001973A2 (en) * 1999-07-01 2001-01-11 Pharmacia & Upjohn Company Highly selective norepinephrine reuptake inhibitors and methods of using the same
CN1969859A (zh) * 1999-07-01 2007-05-30 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
US20090023705A1 (en) * 2007-05-07 2009-01-22 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
US20140275244A1 (en) * 2013-03-13 2014-09-18 Sk Biopharmaceuticals Co., Ltd. Treatment of Cataplexy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001001973A2 (en) * 1999-07-01 2001-01-11 Pharmacia & Upjohn Company Highly selective norepinephrine reuptake inhibitors and methods of using the same
CN1969859A (zh) * 1999-07-01 2007-05-30 法玛西雅厄普约翰美国公司 高度选择性去甲肾上腺素再摄取抑制剂及其用途
US20090023705A1 (en) * 2007-05-07 2009-01-22 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders or attention deficit disorders
US20140275244A1 (en) * 2013-03-13 2014-09-18 Sk Biopharmaceuticals Co., Ltd. Treatment of Cataplexy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OSCAR LARROSA MD等: "Stimulant and Anticataplectic Effects of Reboxetine in Patients with Narcolepsy:APilot Study:APilot Study", 《CLINICAL PHARMACOLOGY》, vol. 24, no. 3, pages 282 - 285 *

Also Published As

Publication number Publication date
MX2022006630A (es) 2022-06-24
IL293536A (en) 2022-08-01
AU2020395082A1 (en) 2022-06-09
EP4069244A1 (de) 2022-10-12
JP2023504685A (ja) 2023-02-06
BR112022010677A2 (pt) 2022-08-16
EP4069244A4 (de) 2023-12-20
CR20220247A (es) 2022-08-18
PE20230181A1 (es) 2023-02-01
CA3163505A1 (en) 2021-06-10
CO2022007507A2 (es) 2022-06-21
KR20220108122A (ko) 2022-08-02

Similar Documents

Publication Publication Date Title
US11364245B2 (en) Use of reboxetine to treat narcolepsy
US11883408B2 (en) Reboxetine to treat narcolepsy
US20210100808A1 (en) Use of reboxetine to treat narcolepsy
CN112888430A (zh) 瑞波西汀治疗发作性睡病的用途
WO2006105117A2 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
CA3223187A1 (en) Combination of dextromethorphan and bupropion for treating depression
CN115697314A (zh) 安非他酮和右美沙芬组合用于治疗神经病症的用途
JP2020533415A (ja) ナルコレプシーの処置におけるガボキサドールの使用
US20220249501A1 (en) Use of esreboxetine to treat nervous system disorders such as fibromyalgia
TWI344840B (en) Modafinil modified release pharmaceutical compositions
CN114746097A (zh) 瑞波西汀治疗神经***障碍的用途
TWI790510B (zh) 瑞波西汀治療神經系統障礙的用途
WO2024077180A1 (en) Use of mazindol to treat nervous system disorders
US20180344745A1 (en) Treatment of developmental disorders with imidazolone derivatives
CN116981450A (zh) 抗抑郁剂和和右美沙芬的组合用于治疗神经精神病症
CN114423417A (zh) 用于对映体富集的或纯的安非他酮的剂型和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40074346

Country of ref document: HK